지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 379 - 380 (2page)
이용수
초록· 키워드
오류제보하기
등록된 정보가 없습니다.
목차
등록된 정보가 없습니다.
참고문헌 (5)
참고문헌 신청
이지연 / 2019 / Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors / Diabetes and Metabolism Journal 43(2):158~173
Strojek K / 2011 / Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride : a randomized, 24-week, double-blind, placebo-controlled trial / Diabetes Obes Metab 13:928~938
Scheen AJ / 2015 / Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes / Expert Opin Drug Saf 14:505~524
Zinman B / 2015 / Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes / N Engl J Med 373:2117~2128
Neal B / 2017 / Canagliflozin and cardiovascular and renal events in type 2 diabetes / N Engl J Med 377:644~657
Strojek K / 2011 / Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride : a randomized, 24-week, double-blind, placebo-controlled trial / Diabetes Obes Metab 13:928~938
Scheen AJ / 2015 / Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes / Expert Opin Drug Saf 14:505~524
Zinman B / 2015 / Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes / N Engl J Med 373:2117~2128
Neal B / 2017 / Canagliflozin and cardiovascular and renal events in type 2 diabetes / N Engl J Med 377:644~657
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Diabetes and Metabolism Journal
2022 .07
-
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Diabetes and Metabolism Journal
2022 .07
-
Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
Korean Circulation Journal
2021 .01
-
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
Diabetes and Metabolism Journal
2019 .01
-
Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7)
Diabetes and Metabolism Journal
2015 .01
-
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2024 .09
-
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
Diabetes and Metabolism Journal
2022 .07
-
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
Diabetes and Metabolism Journal
2021 .01
-
Early Assessment of the Risk for Gestational Diabetes Mellitus: Can Fasting Parameters of Glucose Metabolism Contribute to Risk Prediction? (Diabetes Metab J 2019;43:785-93)
Diabetes and Metabolism Journal
2020 .01
-
Early Assessment of the Risk for Gestational Diabetes Mellitus: Can Fasting Parameters of Glucose Metabolism Contribute to Risk Prediction? (Diabetes Metab J 2019;43:785-93)
Diabetes and Metabolism Journal
2020 .01
-
GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J 2014;38:472-9)
Diabetes and Metabolism Journal
2015 .01
-
GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J 2014;38:472-9)
Diabetes and Metabolism Journal
2015 .01
-
Projection of Diabetes Prevalence in Korean Adults for the Year 2030 Using Risk Factors Identified from National Data (Diabetes Metab J 2019;43:90-6)
Diabetes and Metabolism Journal
2019 .01
-
Projection of Diabetes Prevalence in Korean Adults for the Year 2030 Using Risk Factors Identified from National Data (Diabetes Metab J 2019;43:90-6)
Diabetes and Metabolism Journal
2019 .01
-
Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition (Diabetes Metab J 2023;47:784-95)
Diabetes and Metabolism Journal
2024 .01
-
Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition (Diabetes Metab J 2023;47:784-95)
Diabetes and Metabolism Journal
2024 .01
-
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)
Diabetes and Metabolism Journal
2024 .09
-
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)
Diabetes and Metabolism Journal
2024 .09
-
Clinical Characteristics of Diabetes in People with Mitochondrial DNA 3243A>G Mutation in Korea (Diabetes Metab J 2024;48:482-6)
Diabetes and Metabolism Journal
2024 .07
이 논문의 저자 정보
최근 본 자료
댓글(0)
0